The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1394
July 9, 2012
View Complete Issue         Table of Contents 2019 
An Imaging Agent for Amyloid
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
An Imaging Agent for Amyloid
July 9, 2012 (Issue: 1394)
The FDA has approved florbetapir F18 (flor bay´ ta pir; Amyvid – Lilly), an intravenous radioactive diagnostic agent used with positron emission tomography (PET) scans, to estimate β-amyloid neuritic plaque density in adults being...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: An Imaging Agent for Amyloid
Article code: 1394b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.